Annovis Bio (NYSE:ANVS) Earns “Hold” Rating from D. Boral Capital

Annovis Bio (NYSE:ANVS)‘s stock had its “hold” rating restated by equities research analysts at D. Boral Capital in a research note issued on Monday, Marketbeat Ratings reports.

A number of other research firms have also recently weighed in on ANVS. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Annovis Bio in a report on Monday, November 11th. Maxim Group raised Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Friday, October 25th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.40.

Annovis Bio Trading Down 8.2 %

NYSE:ANVS opened at $2.52 on Monday. The stock has a 50 day moving average of $4.81 and a 200-day moving average of $7.07. The firm has a market capitalization of $35.81 million, a PE ratio of -0.56 and a beta of 1.63. Annovis Bio has a 52 week low of $2.44 and a 52 week high of $20.00.

Institutional Investors Weigh In On Annovis Bio

Several large investors have recently made changes to their positions in ANVS. Greenwich Wealth Management LLC boosted its holdings in shares of Annovis Bio by 9.3% during the 3rd quarter. Greenwich Wealth Management LLC now owns 16,475 shares of the company’s stock worth $133,000 after buying an additional 1,400 shares during the period. JPMorgan Chase & Co. acquired a new position in Annovis Bio during the 3rd quarter worth $31,000. State Street Corp boosted its holdings in Annovis Bio by 23.7% during the third quarter. State Street Corp now owns 36,035 shares of the company’s stock valued at $290,000 after acquiring an additional 6,900 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Annovis Bio during the third quarter valued at about $76,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Annovis Bio in the fourth quarter valued at about $65,000. Institutional investors own 15.83% of the company’s stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.